Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors
Abstract Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type 2 diabetes (T2D) in clinic. Previous studies have shown linagliptin improves β cell function using animal models and is...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/88d07d8e9add4b2fa9564169da40f93b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|